Science & Health

A Harvard professor co-created innovative technology that gives some smartphone users alerts about dangerous seismic activity.

New grants from the Star Friedman Challenge for Promising Scientific Research will support seven cutting-edge research projects led by faculty across Harvard.

Technology born out of Harvard labs shows the power of collaboration and how the path to development seldom follows a straight line.

Harvard chemical biologist Greg Verdine, a force behind a promising experimental treatment for pancreatic cancer, learned the value of improvisational thinking from a devastating family accident.

Professor of organismic and evolutionary biology Mandë Holford uncovers the secrets of venomous sea snails and cephalopods, their toxins, and how those compounds might be turned into medicines for human diseases.

A gift from Lisa and Mark Schwartz AB ’76, MBA ’79, MPP ’79 will provide financial aid to MD-PhD students in the Harvard-MIT Program in Health Sciences and Technology.

Devorah Kranz PhD ’25 brings the creativity and holistic thinking she developed growing up in a Hasidic Jewish community to research on the neurological health of children. By identifying biomarkers of Rett syndrome, Kranz is deepening scientists’ understanding of a much more common condition: autism.

A team led by Harvard bioengineer David Mooney has developed an “Implantable Living Materials” platform, which aims to provide synthetically engineered, living cells that can sense injury or disease-associated conditions in their environment and deliver the right amount of a therapeutic molecule directly to where it’s needed to aid recovery.

A 10-tone skin scale developed by Harvard sociologist Ellis Monk is reshaping medical diagnostics worldwide—helping health care providers more accurately detect conditions in patients with darker skin and saving lives in the process.

After three decades of research, Harvard Medical School professor Merit Cudkowicz achieved a breakthrough in the fight against ALS. A new study co-led by Cudkowicz found that the drug tofersen can radically slow—and in some cases reverse—the course of the disease in a small subset of patients with a rare genetic variant, proving for the first time that this illness can be stopped.